Pediatrix Medical Group, Inc. (MD) Stock Analysis
Healthcare · Medical Care Facilities
Hold if already holding. Not a fresh buy at $24.15, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (3.4% away).
Pediatrix Medical Group operates a national network of approximately 2,295 affiliated physicians providing neonatal, maternal-fetal, and other pediatric subspecialty care at over 360 NICUs and 60 PICUs across 37 states. The company generates revenue through fee-for-service... Read more
Hold if already holding. Not a fresh buy at $24.15, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (3.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-17Recent Developments — Pediatrix Medical Group, Inc.
Latest news
- NEWS Here's why Pediatrix Medical Group (MD) is a strong momentum stock - MSN — MSN positive
- NEWS A Look Back at Healthcare Providers & Services Stocks’ Q4 Earnings: Pediatrix Medical Group (NYSE:MD) Vs The Rest Of The — Yahoo Finance positive
- NEWS Phocas Financial Corp. Acquires 103,328 Shares of Pediatrix Medical Group, Inc. $MD - MarketBeat — MarketBeat positive
- NEWS Is Pediatrix Medical Group Inc (MD) Overvalued After 3.7% Rally? - GuruFocus — GuruFocus neutral
- NEWS Pediatrix Medical Group (MD) Is Up 13.7% After Beating EPS and Reaffirming EBITDA Outlook - Has The Bull Case Changed? - — simplywall.st positive
Generated 2026-06-17T08:56:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicTexas32%10-K Item 1A: 'Texas accounted for approximately 32% of our net revenue in 2025'
Material Events(8-K, last 90d)
- 2026-05-07Item 5.02LOWShareholders approved Second Amended and Restated 2008 Incentive Compensation Plan at May 7, 2026 Annual Meeting, increasing shares available for issuance by 8,000,000. Administrative compensatory arrangement approval; no officer departure or appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $24.15, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (3.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $24.23 (+0.3%), stop $22.79 (−6.0%), A.R:R -1.3:1. Score 5.9/10, moderate confidence.
Take-profit target: $24.23 (+0.3% upside). Target $24.23 (+0.3%), stop $22.79 (−6.0%), A.R:R -1.3:1. Stop-loss: $22.79.
Analyst target reached - limited upside remaining; Near 52-week high (3.4% away); Overbought (RSI 84).
Pediatrix Medical Group, Inc. trades at a P/E of 11.8 (forward 10.3). TrendMatrix value score: 7.8/10. Verdict: Hold.
15 analysts cover MD with a consensus score of 3.9/5. Average price target: $23.
What does Pediatrix Medical Group, Inc. do?Pediatrix Medical Group operates a national network of approximately 2,295 affiliated physicians providing neonatal,...
Pediatrix Medical Group operates a national network of approximately 2,295 affiliated physicians providing neonatal, maternal-fetal, and other pediatric subspecialty care at over 360 NICUs and 60 PICUs across 37 states. The company generates revenue through fee-for-service billings to commercial and government payers; Texas accounted for approximately 32% of net revenue in 2025.